Salute e Benessere
Androgen Receptor Targeted Therapies Market Forecast: Key Trends and Growth Projections Across the 7MM During the Forecast Period (2025-2034) | DelveInsight
Discover which indication is expected to grab the major androgen receptor targeted therapies market share @
Prostate cancer incidence rises strongly with age; global population aging and improved detection are increasing the number of diagnosed patients who may need AR-directed treatment, which expands the addressable population for AR inhibitors and related therapies. In 2024, within the United States , the five-year prevalent cases of mCSPC surpassed those of mCRPC, with approximately cases of mCSPC.
Key approved therapies, such as , have set a high benchmark in terms of efficacy and survival outcomes, driving consistent market growth. These drugs have expanded their indications across various stages of prostate cancer, including non-metastatic and hormone-sensitive settings, which further broadens the patient population.
The competitive landscape is dominated by large pharmaceutical players like , who hold strong patent positions and market access in developed regions.
Androgen receptor-targeted therapies have transformed prostate cancer management and remain a cornerstone of treatment. Key agents like (apalutamide), (enzalutamide), and (darolutamide) have shown strong efficacy, particularly in metastatic castration-resistant prostate cancer (mCRPC), and their use has now expanded across multiple stages of the disease.
ERLEADA is a next-generation oral androgen receptor inhibitor that blocks androgen signaling in prostate cancer cells. It is approved for both nmCRPC and mCSPC. Taken once daily with or without food, ERLEADA received FDA approval in February 2018 for nmCRPC and in September 2019 for mCSPC after priority review. It was also approved by the European Commission in January 2019 for nmCRPC and in January 2020 for mHSPC following the TITAN trial. In Japan , the PMDA approved ERLEADA in March 2019 for nmCRPC and expanded its use for metastatic disease in May 2020 , reflecting its global reach.
XTANDI is an orally bioavailable, non-steroidal androgen receptor inhibitor with antitumor activity. It is indicated for patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. Enzalutamide works via a distinct mechanism compared to other AR antagonists, inhibiting androgen receptor signaling and reducing prostate cancer cell proliferation and PSA levels. Since its initial FDA approval in August 2012 for post-docetaxel mCRPC, XTANDI's indications have steadily broadened — approved in 2014 for mCRPC without prior chemotherapy, in 2018 for both non-metastatic and metastatic CRPC, and in 2019 for mCSPC based on ARCHES trial data. These approvals highlight the drug's expanding importance in prostate cancer care.
The FDA approved darolutamide for mCSPC, making it the first androgen receptor inhibitor approved for mCSPC with or without chemotherapy. In the U.S., NUBEQA is approved in combination with or without docetaxel for mCSPC, and also for non-metastatic castration-resistant prostate cancer. It is currently the only FDA-approved AR inhibitor for mHSPC in combination with ADT, with or without chemotherapy. This latest approval follows positive Phase III ARANOTE trial results, extending darolutamide's indication in mHSPC and reinforcing its favorable safety and tolerability across all approved uses.
Learn more about the androgen receptor targeted therapies @
Several key players, including (Luxdegalutamide), (RO7656594), and others, are involved in developing androgen receptor targeted therapies for various indications, such as prostate cancer, and others.
is an experimental oral PROTAC-based protein degrader specifically engineered to target and eliminate the androgen receptor (AR). In preclinical studies, it has shown effectiveness not only in models with normal AR expression but also in tumors that carry AR mutations or gene amplification — both of which are common resistance mechanisms to currently approved AR-targeted therapies. In April 2024 , Arvinas signed a global licensing agreement with Novartis to develop and commercialize luxdegalutamide (ARV-766) for prostate cancer treatment. This deal also involved transferring the AR-V7 program to Novartis.
is another orally bioavailable androgen receptor degrader with potential anticancer activity. After oral administration, it binds to and induces degradation of the androgen receptor, thereby blocking AR-driven signaling pathways and suppressing the growth of AR-overexpressing tumor cells. The androgen receptor is a hormone-regulated transcription factor essential for tumor growth in castration-resistant prostate cancer (CRPC).
The anticipated launch of these emerging therapies are poised to transform the androgen receptor targeted therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the androgen receptor targeted therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about androgen receptor targeted therapies clinical trials, visit @
Antiandrogens, also called androgen receptor inhibitors or testosterone blockers, are a group of drugs that stop male hormones like testosterone and dihydrotestosterone (DHT) from exerting their effects in the body. They do this either by blocking the androgen receptors or by reducing the production of these hormones. In that sense, they act opposite to androgen receptor agonists such as natural androgens, anabolic steroids (like testosterone, DHT, nandrolone), and selective androgen receptor modulators (SARMs) like enobosarm. Antiandrogens belong to the class of sex hormone antagonists alongside antiestrogens and antiprogestogens.
The androgen receptor targeted therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Discover more about androgen receptor targeted therapies in development @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key prostate cancer companies including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic prostate cancer companies including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key mCRPC companies including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key nmPC companies including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/androgen-receptor-targeted-therapies-market-forecast-key-trends-and-growth-projections-across-the-7mm-during-the-forecast-period-20252034--delveinsight-302539873.html